Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Folegatti, PM, Ewer, KJ, Ramasamy, MN, Minassian, AM, Flaxman, AL, Belij-Rammerstorfer, S, Angus, B, Bittaye, M, Bibi, S, Aley, PK, Voysey, M, Owens, DR, Cathie, K, Babbage, G, Cicconi, P, Clutterbuck, EA, Fuskova, M, Colin-Jones, R, Emary, KRW, Fedosyuk, S, Chappell, H, Charlton, S, Berry, L, Joe, CCD, Hou, MM, Kerridge, S, Dold, C, Lawrie, AM, Kelly, EJ, Gbesemete, D, Green, C, Hallis, B, Makinson, R, Jenkin, D, Marchevsky, NG, Lelliott, A, Plested, E, Munro, APS, Pacurar, M, Mujadidi, Y, Lwin, MN, Rawlinson, T, Ritchie, AJ, Robinson, H, Pollard, AJ, Rhead, S, Amy Ross-Russell, Rand, J, Nisha Singh, Saich, S, Oxford COVID Vaccine Trial Group